Evotec SE : In its CC Evotec predicts strong Q4 – but we see no attractive entry point
>Evotec is confident about a strong Q4 to meet FY guidance - The company appeared quite confident in achieving its 2024 EBITDA guidance of € 15-35m, which requires at least a Q4 adj. EBITDA of € 21.8m after a loss of -€ 6m after nine months. Evotec sees three main drivers for a strong Q4: 1/ a significant increase in sales, which is covered by the current orderbook, this will strongly translate into EBITDA due to high operating leverage, 2/ further cost optimisation w...Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.